Healthcare / Medical DistributionOslo
$17.30
-0.20 (-1.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $23.2M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$415M
P/E
N/A
•EV/EBITDA
18.8x
↑ROE
-7.0%
↓Gross Margin
39.0%
↓Debt/Equity
0.68
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.9%
FCF CAGR
+13.9%
FCF margin
4.1%
FCF / Net income
-0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $565.4M · net income $-23.5M · FCF $23.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $565.4M | $565.4M | $531.4M | $512.0M | $382.1M |
| Net Income | $-23.5M | $-23.5M | $-5.5M | $-13.7M | $29.4M |
| EBITDA | $30.3M | $30.3M | $23.1M | $30.9M | $50.4M |
| EPS | — | — | -0.31 | -0.78 | 1.70 |
| Gross Margin | 39.0% | 39.0% | 39.3% | 38.9% | 42.8% |
| Operating Margin | 2.9% | 2.9% | 6.0% | 7.7% | 11.6% |
| Net Margin | -4.2% | -4.2% | -1.0% | -2.7% | 7.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.68 | 0.68 | 0.65 | 0.85 | 0.30 |
| Current Ratio | 1.47 | 1.47 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $23.2M | $23.2M | $36.0M | $-19000.00 | $15.7M |
| Returns | |||||
| ROE | -7.0% | -7.0% | -2.5% | -6.7% | 14.0% |
| Valuation | |||||
| P/E | — | — | — | — | 20.00 |
| EV/EBITDA | 18.83 | 18.83 | 24.06 | 25.77 | 11.85 |
| P/B | 1.24 | 1.24 | 2.09 | 3.22 | 2.81 |
| Growth & Yield | |||||
| Revenue Growth | 6.4% | 6.4% | 3.8% | 34.0% | — |
| EPS Growth | — | — | 59.7% | -145.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.31 → n/d
Residual
-20.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.